Davletshina N I, Samoylov A N, Lisovskaya S A, Anisimov A N, Aydova A V
Kazan State Medical University, Kazan, Russia.
Republican Clinical Ophthalmological Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia.
Vestn Oftalmol. 2023;139(4):12-19. doi: 10.17116/oftalma202313904112.
Methods of treatment of fungal keratitis in the Russian Federation currently consist of non-standardized off-label methods due to the lack of licensed commercial antifungal solutions designed for use in ophthalmology. The article presents the results of successful treatment of fungal keratitis in experimental animals with a terbinafine solution, with effectiveness comparable to voriconazole lyophilizate diluted to 1%.
The study analyzed the effectiveness of terbinafine solution in the experimental treatment of fungal keratitis.
The study was conducted on Soviet chinchilla rabbits with signs of keratomycosis modeled during the experiment. Fifteen experimental animals were randomly divided into three comparison groups: group 1 received treatment with 1% voriconazole, group 2 - 0.1% terbinafine, group 3 did not receive treatment.
Groups of rabbits treated with voriconazole and terbinafine showed comparable positive treatment results, but in the terbinafine group epithelization was completed earlier, and complete sanitation of the fungal microflora was achieved on day 3.
One important advantage of 0.1% terbinafine suspension lies in availability of a local form designed for ophthalmological application. The advantage of local 0.1% terbinafine suspension is supported by the combination of signs and results, and the obtained data may be used for introducing it into practice after further clinical trials.
由于缺乏经许可用于眼科的商业抗真菌溶液,俄罗斯联邦目前治疗真菌性角膜炎的方法包括非标准化的超说明书用药方法。本文介绍了用特比萘芬溶液成功治疗实验动物真菌性角膜炎的结果,其有效性与稀释至1%的伏立康唑冻干品相当。
本研究分析了特比萘芬溶液在实验性治疗真菌性角膜炎中的有效性。
对在实验过程中模拟角膜真菌病症状的苏联龙猫兔进行研究。15只实验动物随机分为三个对照组:第1组接受1%伏立康唑治疗,第2组接受0.1%特比萘芬治疗,第3组不接受治疗。
用伏立康唑和特比萘芬治疗的兔组显示出相当的积极治疗效果,但在特比萘芬组上皮化完成得更早,并且在第3天实现了真菌微生物群的完全清除。
0.1%特比萘芬混悬液的一个重要优点在于有专门为眼科应用设计的局部剂型。局部0.1%特比萘芬混悬液的优点得到了体征和结果的综合支持,所得数据可在进一步临床试验后用于将其引入实际应用。